Cerus Corporation

NASDAQ:CERSHealthcare · Medical - Devices

Mkt Cap$459.48M

Float192.48M

Shares O/S201.52M

Inst Own74.4%

SI8.6%

Dilution

-6.56%$2.28

AH$2.28+0.00%vs close

Mkt Cap$459.48M

Float192.48M

O/S201.52M

Vol

$ Vol

RVOL

Inst Own74.4%

SI8.6%

Earnings

Dilution

NASDAQ:CERS$2.28-6.56%

MCap$459.48M

Float192.48M

O/S201.52M

SI8.6%

Inst Own74.4%

Dilution

Phase Distribution

17 lead-sponsored trials·2 active·11 completed

Phase 11

Phase 28

Phase 35

Not applicable3

(7 more as collaborator)

Status Overview

Not yet recruiting1

Recruiting2

Completed11

Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials

Sponsor role

Status

Phase

Phase 3
Completed
Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
Transfusion of Pathogen Inactivated Platelets stored for 6-7 days
Thrombocytopenia
Enrollment
211
Start
Oct 2005
Primary Completion
Jul 2009
Completion
Jul 2009
NCT00261924
Phase 3
Completed
Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia
S-303 Red Blood Cells (RBCs) - Test, Conventional, untreated red blood cells (RBCs) - Control
Focus:Use of S303 RBCs in Patients With Acute Anemia
Enrollment
81
Start
Apr 2013
Primary Completion
Jul 2014
Completion
Oct 2014
NCT01716923
Phase 3
Completed
Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
S-303 Treated Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells
Thalassemia Major
Enrollment
86
Start
Dec 2012
Primary Completion
Dec 2017
Completion
Dec 2017
NCT01740531
Phase 3
Completed
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Anemia
Enrollment
692
Start
May 2017
Primary Completion
Apr 2026
Completion
Jul 2026
NCT03037164
Phase 3
Completed
Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
INTERCEPT, Control
Anemia
Enrollment
581
Start
Dec 2018
Primary Completion
Dec 2023
Completion
Mar 2024
NCT03459287
Phase 2
Completed
A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells
S303 Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells (RBCs)
Focus: Assess Post Infusion Viability of S303 RBCs
Enrollment
42
Start
Oct 2012
Primary Completion
Jul 2014
Completion
Nov 2014
NCT01711346
Phase 2
Completed
A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma
INTERCEPT treated platelets
Healthy
Enrollment
14
Start
Dec 2014
Primary Completion
May 2015
Completion
Sep 2015
NCT02310412
Phase 2
Terminated
A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets., Autologous apheresis Conventional untreated Platelet Components
Healthy
Enrollment
14
Start
Dec 2015
Primary Completion
May 2016
Completion
May 2016
NCT02653443
Phase 2
Completed
In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
INTERCEPT Treated Platelets
Healthy
Enrollment
37
Start
Nov 2019
Primary Completion
Apr 2021
Completion
Apr 2021
NCT04022889
Phase 2
Completed
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
INTERCEPT Blood System for Platelets with LED Illuminator
Healthy Subjects
Enrollment
40
Start
Jan 2025
Primary Completion
Jun 2025
Completion
Jun 2025
NCT06697223
Phase 2
Recruiting
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs
Healthy Subjects
Enrollment
120
Start
Sep 2025
Primary Completion
Dec 2026est.
Completion
Feb 2027est.
NCT07015437
Phase 2
Not yet recruiting
Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs
Transfusion Reaction, Hemolytic
Enrollment
25
Start
Oct 2026est.
Primary Completion
Sep 2030est.
Completion
Dec 2030est.
NCT07152379
Phase 2
Withdrawn
Biotin-Acridine Red Cell Exchange Kinetics
Pathogen reduced red blood cells
Sickle Cell Disease
Enrollment
0
Start
Oct 2025est.
Primary Completion
Sep 2026est.
Completion
Dec 2026est.
NCT07155031
Phase 1
Terminated
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
INTERCEPT Plasma
Acute Ebola Virus Disease
Enrollment
6
Start
Dec 2014
Primary Completion
Dec 2020
Completion
Dec 2020
NCT02295501
Observational
Completed
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
INTERCEPT Platelets
Chikungunya Virus, Dengue Virus
Enrollment
90
Start
Mar 2015
Primary Completion
May 2016
Completion
May 2016
NCT02305732
Observational
Completed
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
Standard of Care
Transfusion Related Acute Lung Injury
Enrollment
2,291
Start
Dec 2015
Primary Completion
Sep 2020
Completion
May 2021
NCT02549222
Observational
Enrolling by invitation
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Hypofibrinogenemia, Hemorrhage +2
Enrollment
320
Start
Sep 2026
Primary Completion
Jul 2028est.
Completion
Aug 2028est.
NCT07218185

		Drug / Therapy	Title	Conditions	Enrollment				Link
Phase 3	Completed	Transfusion of Pathogen Inactivated Platelets stored for 6-7 days	Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days	Thrombocytopenia	211	Oct 2005	Jul 2009	Jul 2009	NCT00261924
Phase 3	Completed	S-303 Red Blood Cells (RBCs) - Test, Conventional, untreated red blood cells (RBCs) - Control	Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia	Focus:Use of S303 RBCs in Patients With Acute Anemia	81	Apr 2013	Jul 2014	Oct 2014	NCT01716923
Phase 3	Completed	S-303 Treated Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells	Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion	Thalassemia Major	86	Dec 2012	Dec 2017	Dec 2017	NCT01740531
Phase 3	Completed	INTERCEPT Blood System for Red Blood Cells, Conventional (Control)	INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections	Anemia	692	May 2017	Apr 2026	Jul 2026	NCT03037164
Phase 3	Completed	INTERCEPT, Control	Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients	Anemia	581	Dec 2018	Dec 2023	Mar 2024	NCT03459287
Phase 2	Completed	S303 Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells (RBCs)	A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells	Focus: Assess Post Infusion Viability of S303 RBCs	42	Oct 2012	Jul 2014	Nov 2014	NCT01711346
Phase 2	Completed	INTERCEPT treated platelets	A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma	Healthy	14	Dec 2014	May 2015	Sep 2015	NCT02310412
Phase 2	Terminated	Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets., Autologous apheresis Conventional untreated Platelet Components	A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study	Healthy	14	Dec 2015	May 2016	May 2016	NCT02653443
Phase 2	Completed	INTERCEPT Treated Platelets	In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days	Healthy	37	Nov 2019	Apr 2021	Apr 2021	NCT04022889
Phase 2	Completed	INTERCEPT Blood System for Platelets with LED Illuminator	A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.	Healthy Subjects	40	Jan 2025	Jun 2025	Jun 2025	NCT06697223
Phase 2	Recruiting	INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs	A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1	Healthy Subjects	120	Sep 2025	Dec 2026est.	Feb 2027est.	NCT07015437
Phase 2	Not yet recruiting	30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs	Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs	Transfusion Reaction, Hemolytic	25	Oct 2026est.	Sep 2030est.	Dec 2030est.	NCT07152379
Phase 2	Withdrawn	Pathogen reduced red blood cells	Biotin-Acridine Red Cell Exchange Kinetics	Sickle Cell Disease	0	Oct 2025est.	Sep 2026est.	Dec 2026est.	NCT07155031
Phase 1	Terminated	INTERCEPT Plasma	A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease	Acute Ebola Virus Disease	6	Dec 2014	Dec 2020	Dec 2020	NCT02295501
Observational	Completed	INTERCEPT Platelets	A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components	Chikungunya Virus, Dengue Virus	90	Mar 2015	May 2016	May 2016	NCT02305732
Observational	Completed	Standard of Care	A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components	Transfusion Related Acute Lung Injury	2,291	Dec 2015	Sep 2020	May 2021	NCT02549222
Observational	Enrolling by invitation	Pathogen Reduced Cryoprecipitated Fibrinogen Complex	Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage	Hypofibrinogenemia, Hemorrhage	320	Sep 2026	Jul 2028est.	Aug 2028est.	NCT07218185

Search ClinicalTrials.gov for “Cerus”